|Genomic classification of cutaneous melanoma|
R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ...
Cell 161 (7), 1681-1696, 2015
|The immune landscape of cancer|
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
|Integrated genomic characterization of papillary thyroid carcinoma|
N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi, SL Asa, JT Auman, ...
Cell 159 (3), 676-690, 2014
|A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer|
FR Khuri, J Nemunaitis, I Ganly, J Arseneau, IF Tannock, L Romel, ...
Nature medicine 6 (8), 879-885, 2000
|Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs|
MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ...
Jama 311 (19), 1998-2006, 2014
|Comprehensive characterization of cancer driver genes and mutations|
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
|Oncogenic signaling pathways in the cancer genome atlas|
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
|An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics|
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
|Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer|
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
|The BATTLE trial: personalizing therapy for lung cancer|
ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein, A Tsao, ...
Cancer discovery 1 (1), 44-53, 2011
|Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition|
SY Sun, LM Rosenberg, X Wang, Z Zhou, P Yue, H Fu, FR Khuri
Cancer research 65 (16), 7052-7058, 2005
|Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer|
SG Swisher, JA Roth, J Nemunaitis, DD Lawrence, BL Kemp, ...
Journal of the National Cancer Institute 91 (9), 763-771, 1999
|Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth|
T Hitosugi, S Kang, MG Vander Heiden, TW Chung, S Elf, K Lythgoe, ...
Science signaling 2 (97), ra73-ra73, 2009
|Integrated genomic characterization of oesophageal carcinoma|
Cancer Genome Atlas Research Network
Nature 541 (7636), 169, 2017
|Perspectives for cancer prevention with natural compounds|
ARMR Amin, O Kucuk, FR Khuri, DM Shin
Journal of clinical oncology 27 (16), 2712, 2009
|Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer|
J Nemunaitis, F Khuri, I Ganly, J Arseneau, M Posner, E Vokes, J Kuhn, ...
Journal of Clinical Oncology 19 (2), 289-298, 2001
|Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck …|
R Haddad, A O'Neill, G Rabinowits, R Tishler, F Khuri, D Adkins, J Clark, ...
The lancet oncology 14 (3), 257-264, 2013
|Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer|
FR Khuri, H Wu, JJ Lee, BL Kemp, R Lotan, SM Lippman, L Feng, ...
Clinical Cancer Research 7 (4), 861-867, 2001
|Clonal genetic alterations in the lungs of current and former smokers|
L Mao, JS Lee, JM Kurie, YH Fan, SM Lippman, A Broxson, FR Khuri, ...
Journal of the National Cancer Institute 89 (12), 857-862, 1997
|Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial|
J Nemunaitis, I Ganly, F Khuri, J Arseneau, J Kuhn, T McCarty, S Landers, ...
Cancer research 60 (22), 6359-6366, 2000